retatrutide glucagon receptor Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data | Current Obesity Reports JK - 🔬 EDUCATIONAL POST:

Retatrutides 24.2% weight loss result comes from a 338-person Phase 2 trial with a relatively homogeneous population it cannot be directly compared to Tirzepatides 2,539-person Phase 3 SURMOUNT-1 data without acknowledging this statistical limitation

The USC study came with some major caveats however: It assumed 100 percent uptake, perfect compliance, and continual use by beneficiaries for the rest of their lives conditions that are not achievable in practice, to quote CBO

Cold medication can feel uncomfortable under the tongue and may trigger an immediate swallowing response in some people

Reduced Risk of Cardiovascular Disease: It has shown potential in lowering risk factors for cardiovascular diseases, such as high blood pressure and cholesterol levels, contributing to overall heart health

Both compounded and brand-name GLP-1 options (Wegovy, Zep

Adults with a BMI 30 or 27 with weight-related conditions